Credit Suisse Global Healthcare Conference (Vical) - Nov 16, 2012 - Anticipated top line results from P3 trial for melanoma by mid-2013
Anticipated P3 data: top line • Melanoma
|
|
Allovectin-7
-- -- --
Lee H. Kalowski - Credit Suisse Securities (USA) LLC.
All right good afternoon everyone. Let’s want to we get started our next company is Vical, who’s lead product is Allovectin current in Phase III for melanoma. So latest, which they said the data should be available in next year, here to talk
about Allovectin and Vical is a Vijay Samant, President and CEO. Thank you.
So I think the track record of dealing with the agency. So in terms of upcoming milestones top line data from Allovectin in middle of 2013 significant progress both on the hematopoietic cell transplants by Astellas in 2013, that are four piece
templates therapeutic vaccine in 2013, so some of you where new to the Vical store here is a platform company with the broad technology strong IP a pivtol phase III a factorable assets which is a very good phase II data two programs
partnered with one of the big pharma Japanese companies and pretty intense pipeline beside well. Thank you.
-- -- --
|